Pneumology - Original Articles Open access

Role of inhaled corticosteroids/formoterol in relieving acute asthma as compared to traditional salbutamol in children 6 to 11 years old on maintenance and reliever therapy step 3 and above as per the Global Initiative for Asthma guideline

Authors

Published
11 June 2025
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2025.3355

Abstract

The recent Global Initiative for Asthma (GINA) guidelines offer two reliever therapy options for patients on step 3 and above: the more popularly used short-acting β-agonists (SABA) and the newly introduced inhaled corticosteroids (ICS)-formoterol combination. Our aim was to assess the effectiveness of the ICS/formoterol combination in comparison to the traditional SABA offered to patients aged 6-11 years old following step 3 and above of the GINA guidelines. A retrospective study was conducted at a tertiary care facility in Karachi, Pakistan. The study involved children aged 6-11 years old who were admitted with an asthma exacerbation and were subsequently discharged on step 3 and above as per the GINA guidelines for 3 months. The patients were then categorized into two groups depending on the type of reliever used (ICS/formoterol or salbutamol). There were 80 pediatric patients enrolled in our study. The emergency room visits with asthma exacerbation in 3 months following discharge were significantly lower in the ICS/formoterol reliever group (1.27±0.83) than in the salbutamol reliever group (1.93±1.36) (p=0.01). Mean admissions with asthma in 6 months post-discharge were significantly higher in the salbutamol group (2.18±0.82) as compared to the ICS/formoterol group (1.24±0.83). Moreover, the number of patients requiring step-up control within 3 months of discharge was also significantly lower in the ICS/formoterol group, with 2 patients, than in the salbutamol group, with 10 patients (p=0.02). The forced expiratory volume in 1 second value 3 months after discharge was significantly greater in the ICS/formoterol group (91.27±8.32) than in the salbutamol group (84.58±10.44) (p=0.02). Through our analysis, we were able to highlight the superiority of ICS/formoterol as a reliever compared to SABA for moderate asthma.

Keywords

Ethics Approval

Approval was received by the Ethics Review Committee (2024-10088-29895) at Aga Khan University Hospital.

References

  1. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract 2017;5:918-27. DOI: https://doi.org/10.1016/j.jaip.2017.05.001
  2. Reddel HK, Bacharier LB, Bateman EDet al. Global Initiative for Asthma (GINA) Strategy 2021 – executive summary and rationale for key changes. Am J Respir Crit Care Med 2021;205:17-35. DOI: https://doi.org/10.1164/rccm.202109-2205PP
  3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Available from: https://ginasthma.org/2023-gina-main-report/.
  4. Kaplan A, Mitchell PD, Cave AJ, et al. Effective asthma management: is it time to let the AIR out of SABA? J Clin Med 2020;9:921. DOI: https://doi.org/10.3390/jcm9040921
  5. Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006;19:139-47. DOI: https://doi.org/10.1016/j.pupt.2005.04.009
  6. BMJ Best Practice. Acute asthma exacerbation in adults. Available from: https://bestpractice.bmj.com/topics/en-gb/3000085#:~:text=Definition
  7. Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012;129:S34-48. DOI: https://doi.org/10.1016/j.jaci.2011.12.983
  8. Wang Z, Li Y, Gao Y, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir Res 2023;24:169. DOI: https://doi.org/10.1186/s12931-023-02475-6
  9. Ozseker ZF, Aksu K, Mutlu LC, et al. Expert opinion on practice patterns in mild asthma after the GINA 2019 updates: a major shift in treatment paradigms from a long-standing SABA-only approach to a risk reduction–based strategy with the use of symptom-driven (as-needed) low-dose ICS/LABA. Curr Allergy Asthma Rep 2022;22:123-34. DOI: https://doi.org/10.1007/s11882-022-01038-x
  10. Sriprasart T, Waterer G, Garcia G, et al. Safety of SABA monotherapy in asthma management: a systematic review and meta-analysis. Adv Ther 2022;40:133-58. DOI: https://doi.org/10.1007/s12325-022-02356-2
  11. Bruce P, Hatter L, Houghton C, et al. The anti-inflammatory reliever (AIR) algorithm study: a protocol for a single-group study of an AIR stepwise approach to the treatment of adult asthma. ERJ Open Res 2023;9:00239-2023. DOI: https://doi.org/10.1183/23120541.00239-2023
  12. Krings JG, Beasley R. The role of ICS-containing rescue therapy versus SABA alone in asthma management today. J Allergy Clin Immunol Pract 2024;12:870-9. DOI: https://doi.org/10.1016/j.jaip.2024.01.011
  13. Bruce P, Hatter L, Beasley R. Anti‐inflammatory reliever therapy in asthma: the evidence mounts but more is needed. Respirology 2020;25:776-8. DOI: https://doi.org/10.1111/resp.13889
  14. Beasley R, Braithwaite I, Semprini A, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J 2020;55:1901407. DOI: https://doi.org/10.1183/13993003.01407-2019
  15. Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2013;69:130-6. DOI: https://doi.org/10.1136/thoraxjnl-2013-203557
  16. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787-94. DOI: https://doi.org/10.1183/09031936.03.00055803
  17. Tattersfield AE, Löfdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001;357:257-61. DOI: https://doi.org/10.1016/S0140-6736(00)03611-4
  18. Beasley R, Harper J, Bird G, et al. Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma. BMC Pulm Med 2019;19:264. DOI: https://doi.org/10.1186/s12890-019-1014-4
  19. O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36. DOI: https://doi.org/10.1164/rccm.200407-884OC
  20. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-36. DOI: https://doi.org/10.1111/j.1742-1241.2007.01338.x

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.